Raiffeisen Bank International AG Purchases Shares of 88,496 Boston Scientific Co. (NYSE:BSX)

Raiffeisen Bank International AG acquired a new stake in shares of Boston Scientific Co. (NYSE:BSX - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 88,496 shares of the medical equipment provider's stock, valued at approximately $7,936,000.

Other large investors have also modified their holdings of the company. Point72 Hong Kong Ltd acquired a new position in shares of Boston Scientific in the 4th quarter valued at $1,904,000. Polar Asset Management Partners Inc. increased its stake in Boston Scientific by 69.0% in the fourth quarter. Polar Asset Management Partners Inc. now owns 481,717 shares of the medical equipment provider's stock valued at $43,027,000 after acquiring an additional 196,617 shares during the period. ProShare Advisors LLC raised its position in Boston Scientific by 12.0% in the fourth quarter. ProShare Advisors LLC now owns 224,880 shares of the medical equipment provider's stock worth $20,086,000 after purchasing an additional 24,022 shares in the last quarter. Quantinno Capital Management LP lifted its stake in Boston Scientific by 47.3% during the fourth quarter. Quantinno Capital Management LP now owns 134,139 shares of the medical equipment provider's stock worth $11,981,000 after purchasing an additional 43,050 shares during the period. Finally, Pathstone Holdings LLC lifted its stake in Boston Scientific by 1.3% during the fourth quarter. Pathstone Holdings LLC now owns 126,091 shares of the medical equipment provider's stock worth $11,263,000 after purchasing an additional 1,659 shares during the period. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Boston Scientific Trading Up 0.5%

Shares of NYSE:BSX traded up $0.57 during mid-day trading on Monday, reaching $106.61. The stock had a trading volume of 7,933,850 shares, compared to its average volume of 6,369,172. The firm has a market cap of $157.72 billion, a PE ratio of 85.29, a price-to-earnings-growth ratio of 2.79 and a beta of 0.68. The firm has a 50 day simple moving average of $99.18 and a two-hundred day simple moving average of $96.74. The company has a current ratio of 1.08, a quick ratio of 1.02 and a debt-to-equity ratio of 0.41. Boston Scientific Co. has a twelve month low of $71.88 and a twelve month high of $107.17.

Boston Scientific (NYSE:BSX - Get Free Report) last posted its earnings results on Wednesday, April 23rd. The medical equipment provider reported $0.75 earnings per share for the quarter, topping the consensus estimate of $0.67 by $0.08. Boston Scientific had a net margin of 11.07% and a return on equity of 17.80%. The company had revenue of $4.66 billion for the quarter, compared to analyst estimates of $4.57 billion. During the same period last year, the business posted $0.56 earnings per share. The business's revenue for the quarter was up 20.9% compared to the same quarter last year. On average, research analysts predict that Boston Scientific Co. will post 2.85 EPS for the current fiscal year.

Insider Buying and Selling

In other Boston Scientific news, EVP John Bradley Sorenson sold 2,657 shares of the stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $104.41, for a total transaction of $277,417.37. Following the completion of the transaction, the executive vice president now owns 24,294 shares in the company, valued at approximately $2,536,536.54. This represents a 9.86% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Vance R. Brown sold 4,826 shares of the stock in a transaction dated Monday, April 21st. The stock was sold at an average price of $95.09, for a total value of $458,904.34. Following the transaction, the senior vice president now owns 36,193 shares of the company's stock, valued at approximately $3,441,592.37. The trade was a 11.77% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 265,820 shares of company stock valued at $27,406,958. 0.50% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of brokerages have recently issued reports on BSX. Royal Bank of Canada increased their target price on Boston Scientific from $116.00 to $120.00 and gave the stock an "outperform" rating in a report on Thursday, April 24th. StockNews.com upgraded shares of Boston Scientific from a "hold" rating to a "buy" rating in a research note on Tuesday, April 29th. BTIG Research reaffirmed a "buy" rating and set a $124.00 price objective on shares of Boston Scientific in a report on Wednesday, April 23rd. Raymond James boosted their price objective on Boston Scientific from $119.00 to $122.00 and gave the stock a "strong-buy" rating in a research note on Thursday, February 6th. Finally, Robert W. Baird raised their target price on Boston Scientific from $115.00 to $120.00 and gave the company an "outperform" rating in a research note on Thursday, April 24th. Twenty-three investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Buy" and an average price target of $114.74.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.